- Home
- FBIO vs ECOR Comparison
FBIO vs ECOR Comparison
Compare FBIO & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FBIO | ECOR |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.7M | 39.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | FBIO | ECOR |
|---|---|---|
| Price | $2.94 | $4.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $16.50 | ★ $25.50 |
| AVG Volume (30 Days) | ★ 313.3K | 32.4K |
| Earning Date | 11-14-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $62,303,000.00 | $29,835,000.00 |
| Revenue This Year | $29.71 | $28.61 |
| Revenue Next Year | $49.34 | $41.21 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 27.90 |
| 52 Week Low | $1.33 | $4.16 |
| 52 Week High | $4.20 | $19.49 |
Technical Indicators
Market Signals| Indicator | FBIO | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 59.69 | 43.14 |
| Support Level | $2.49 | $4.78 |
| Resistance Level | $3.00 | $5.09 |
| Average True Range (ATR) | 0.15 | 0.21 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 86.41 | 4.88 |
Price Performance
Historical ComparisonAbout FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.